

Product Information



INDICATIONS

XPOVIO® (selinexor) is a prescription medicine approved:

- In combination with bortezomib and dexamethasone (XVd) for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
- In combination with dexamethasone (Xd) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody.
- For the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least 2 lines of systemic therapy. This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).

DISTRIBUTION

XPOVIO can be accessed through the following authorized specialty pharmacies and specialty distributors:

Authorized Specialty Pharmacy

Onco360 Oncology Pharmacy	1.877.662.6633	onco360.com	Fax 1.877.662.6355
---------------------------	----------------	-------------	--------------------

Authorized Specialty Distributors

ASD Healthcare	1.800.746.6273	asdhealthcare.com
Cardinal Health Specialty Distribution	1.866.677.4844	specialtyonline.cardinalhealth.com
McKesson Plasma & Biologics	1.877.625.2566	connect.mckesson.com
McKesson Specialty	1.800.482.6700	mcs.mckesson.com
Oncology Supply	1.800.633.7555	oncologysupply.com

Contact an XPOVIO field representative at XPOVIOpro.com



A patient support program by Karyopharm dedicated to providing assistance and resources to patients and their caregivers for XPOVIO® (selinexor) treatment.

KaryForward can assist with:



Insurance Coverage



Financial Assistance



Support and Resources

To learn more, call 1-877-KARY4WD (1-877-527-9493), Monday through Friday, 8am-8pm ET or visit KaryForward.com.

Please see full Prescribing Information.

For medical information, to report an adverse event or product complaint, please call: 1-888-209-9326 or email: medicalinformation@karyopharm.com.

© 2024 Karyopharm Therapeutics Inc. All rights reserved. US-XPOV-12/20-00018 (01/24)



Product Information (cont'd)



HOW SUPPLIED

- XPOVIO 20 mg tablets are blue, round, bi-convex, film-coated debossed with “K20” on one side and nothing on the other side.
- XPOVIO 40 mg tablets are blue, oval, film-coated, debossed on both sides with “X40”.
- XPOVIO 50 mg tablets are blue, oval, film-coated, debossed on both sides with “X50”.
- XPOVIO 60 mg tablets are blue, oval, film-coated, debossed on both sides with “X60”.

Tablets are packaged in a child-resistant blister pack. Four blister packs are supplied per carton.

For Multiple Myeloma (MM)

NDC	Contents	Tablets per Blister Pack	Weekly Dose	Carton
<u>NDC 72237-103-05</u>	4 weekly blister packs (8 tablets total per carton)	Two 50-mg tablets	100 mg once weekly	
<u>NDC 72237-102-02</u>	4 weekly blister packs (8 tablets total per carton)	Two 40-mg tablets	80 mg once weekly	
<u>NDC 72237-104-01</u>	4 weekly blister packs (4 tablets total per carton)	One 60-mg tablet	60 mg once weekly	
<u>NDC 72237-102-07</u>	4 weekly blister packs (4 tablets total per carton)	One 40-mg tablet	40 mg once weekly	
<u>NDC 72237-101-04</u>	4 blister packs (32 tablets total per carton)	Eight 20-mg tablets	80 mg twice weekly	

For RR DLBCL

NDC	Contents	Tablets per Blister Pack	Weekly Dose	Carton
<u>NDC 72237-101-03</u>	4 blister packs (24 tablets total per carton)	Six 20-mg tablets	60 mg twice weekly	
<u>NDC 72237-102-06</u>	4 weekly blister packs (8 tablets total per carton)	Two 40-mg tablets	40 mg twice weekly	
<u>NDC 72237-104-01</u>	4 weekly blister packs (4 tablets total per carton)	One 60-mg tablet	60 mg once weekly	
<u>NDC 72237-102-07</u>	4 weekly blister packs (4 tablets total per carton)	One 40-mg tablet	40 mg once weekly	

STORAGE

Store at or below 30°C (86°F).

Please see full [Prescribing Information](#).

For medical information, to report an adverse event or product complaint, please call: 1-888-209-9326 or email: medicalinformation@karyopharm.com.

© 2024 Karyopharm Therapeutics Inc. All rights reserved. US-XPOV-12/20-00018 (01/24)

